These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 29499876)

  • 1. Progress in the treatment of Friedreich ataxia.
    Tai G; Corben LA; Yiu EM; Milne SC; Delatycki MB
    Neurol Neurochir Pol; 2018 Mar; 52(2):129-139. PubMed ID: 29499876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological therapeutics in Friedreich ataxia: the present state.
    Strawser C; Schadt K; Hauser L; McCormick A; Wells M; Larkindale J; Lin H; Lynch DR
    Expert Rev Neurother; 2017 Sep; 17(9):895-907. PubMed ID: 28724340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Friedreich ataxia: an update on animal models, frataxin function and therapies.
    González-Cabo P; Llorens JV; Palau F; Moltó MD
    Adv Exp Med Biol; 2009; 652():247-61. PubMed ID: 20225031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small molecules affecting transcription in Friedreich ataxia.
    Gottesfeld JM
    Pharmacol Ther; 2007 Nov; 116(2):236-48. PubMed ID: 17826840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omaveloxolone: potential new agent for Friedreich ataxia.
    Lynch DR; Johnson J
    Neurodegener Dis Manag; 2021 Apr; 11(2):91-98. PubMed ID: 33430645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell and gene therapy for Friedreich ataxia: progress to date.
    Evans-Galea MV; Pébay A; Dottori M; Corben LA; Ong SH; Lockhart PJ; Delatycki MB
    Hum Gene Ther; 2014 Aug; 25(8):684-93. PubMed ID: 24749505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New developments in pharmacotherapy for Friedreich ataxia.
    Clay A; Hearle P; Schadt K; Lynch DR
    Expert Opin Pharmacother; 2019 Oct; 20(15):1855-1867. PubMed ID: 31311349
    [No Abstract]   [Full Text] [Related]  

  • 8. Erythropoietin in Friedreich ataxia.
    Mariotti C; Nachbauer W; Panzeri M; Poewe W; Taroni F; Boesch S
    J Neurochem; 2013 Aug; 126 Suppl 1():80-7. PubMed ID: 23859343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathophysiogical and therapeutic progress in Friedreich ataxia.
    Puccio H; Anheim M; Tranchant C
    Rev Neurol (Paris); 2014 May; 170(5):355-65. PubMed ID: 24792433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic approaches for the treatment of Friedreich's ataxia.
    Strawser CJ; Schadt KA; Lynch DR
    Expert Rev Neurother; 2014 Aug; 14(8):949-57. PubMed ID: 25034024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia.
    Rötig A; de Lonlay P; Chretien D; Foury F; Koenig M; Sidi D; Munnich A; Rustin P
    Nat Genet; 1997 Oct; 17(2):215-7. PubMed ID: 9326946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of expression from the FRDA genomic locus for the therapy of Friedreich ataxia.
    Sarsero JP; Li L; Wardan H; Sitte K; Williamson R; Ioannou PA
    J Gene Med; 2003 Jan; 5(1):72-81. PubMed ID: 12516053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels.
    Yiu EM; Tai G; Peverill RE; Lee KJ; Croft KD; Mori TA; Scheiber-Mojdehkar B; Sturm B; Praschberger M; Vogel AP; Rance G; Stephenson SE; Sarsero JP; Stockley C; Lee CY; Churchyard A; Evans-Galea MV; Ryan MM; Lockhart PJ; Corben LA; Delatycki MB
    J Neurol; 2015 May; 262(5):1344-53. PubMed ID: 25845763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lentivirus-meditated frataxin gene delivery reverses genome instability in Friedreich ataxia patient and mouse model fibroblasts.
    Khonsari H; Schneider M; Al-Mahdawi S; Chianea YG; Themis M; Parris C; Pook MA; Themis M
    Gene Ther; 2016 Dec; 23(12):846-856. PubMed ID: 27518705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Animal and cellular models of Friedreich ataxia.
    Perdomini M; Hick A; Puccio H; Pook MA
    J Neurochem; 2013 Aug; 126 Suppl 1():65-79. PubMed ID: 23859342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond loss of frataxin: the complex molecular pathology of Friedreich ataxia.
    Evans-Galea MV; Lockhart PJ; Galea CA; Hannan AJ; Delatycki MB
    Discov Med; 2014 Jan; 17(91):25-35. PubMed ID: 24411698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infectious delivery and expression of a 135 kb human FRDA genomic DNA locus complements Friedreich's ataxia deficiency in human cells.
    Gomez-Sebastian S; Gimenez-Cassina A; Diaz-Nido J; Lim F; Wade-Martins R
    Mol Ther; 2007 Feb; 15(2):248-54. PubMed ID: 17235301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conditional mouse models for Friedreich ataxia, a neurodegenerative disorder associating cardiomyopathy.
    Puccio H
    Handb Exp Pharmacol; 2007; (178):365-75. PubMed ID: 17203663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of diazoxide on Friedreich ataxia models.
    Santoro A; Anjomani Virmouni S; Paradies E; Villalobos Coa VL; Al-Mahdawi S; Khoo M; Porcelli V; Vozza A; Perrone M; Denora N; Taroni F; Merla G; Palmieri L; Pook MA; Marobbio CMT
    Hum Mol Genet; 2018 Mar; 27(6):992-1001. PubMed ID: 29325032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitochondrial dysfunction in friedreich's ataxia.
    Lodi R; Taylor DJ; Schapira AH
    Biol Signals Recept; 2001; 10(3-4):263-70. PubMed ID: 11351132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.